Latest Soligenix News & Updates

See the latest news and media coverage for Soligenix. We track all announcements, press releases, and industry mentions in real time, all in one place.

Soligenix

Late-stage biopharmaceutical company for rare diseases

soligenix.com

Headquarters: Princeton, United States
Founded year: 1987
Company type: Public company
Number of employees: 25–50
Industry: Pharmaceuticals

Last updated Today

Latest news about Soligenix

In short: Soligenix halted its HyBryte program following a failed Phase 3 trial, leading to a pipeline refocus and increased equity offerings.

Company announcements

June 8 Soligenix

Soligenix applies for Bundibugyo Ebola vaccine funding

The company plans to submit an application to CEPI by June 12, 2026, leveraging its ThermoVax platform and prior filovirus vaccine data.

May 26 Soligenix

Soligenix notes suitability of its vaccine platform for Bundibugyo virus

The platform could enable rapid development of a thermostable subunit vaccine for the ongoing Ebola outbreak in Congo.

May 8 Soligenix

Soligenix announces Q1 2026 financial results and FLASH2 study halt

Net loss was $2.8 million; cash $6.0 million; FLASH2 trial halted for futility; strategic options including M&A to be evaluated.

April 28 Soligenix

Soligenix announces interim results from Phase 3 FLASH2 trial

The Data Monitoring Committee recommended the study be halted for futility. Soligenix will evaluate strategic options including M&A and advancing dusquetide.

Media coverage

June 28 The Globe and Mail

Soligenix Expands At-the-Market Equity Offering Capacity

Soligenix ( (SNGX)) has shared an announcement. On June 26, 2026, Soligenix, Inc. increased the maximum aggregate amount of common stock it may issue under...

June 13 The Globe and Mail

Soligenix Halts HyBryte Program, Refocuses Pipeline Strategy

The score is primarily constrained by weak financial performance (no revenue, persistent net losses, and significant cash burn) despite improved leverage. Technicals also remain negative...

May 31 USA Today

Soligenix (NASDAQ: SNGX) Receives EU Orphan Drug Designation For Dusquetide In Behçet Disease

Soligenix (NASDAQ: SNGX) announced the European Commission has granted orphan drug designation to dusquetide (SGX945) for the treatment of Behçet Disease, following a positive recommendation...

May 26 Yahoo Finance

SNGX Stock More Than Doubles In Pre-Market, Eyes $1 Breakout For First Time In A Month – Ebola Vaccine Optimism Fuels Retail Frenzy

Soligenix shares are also poised to break above the 100-day moving average for the first time in a month, following a four-session rally.

Never miss news about Soligenix

Track Soligenix and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Soligenix competitors & trending companies

Browse news for competitors to Soligenix and other trending companies.